October 15, 2026 · Phase 2 readout
ABOS Phase 2 readout: a negative outcome, -90.8%
On October 15, 2026, sabirnetug — Acumen Pharmaceuticals, Inc. (Alzheimer Disease) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -90.8% in the window around the event.
The move
$2.29
1d before
$0.21
Event day
$0.21
1d after
$0.21
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.3% expected); the stock actually moved -90.8%. Model confidence at the time: 200%.
See the full scored track recordPre-catalyst setup
+1.8%
30-day run-up
9586%
30-day volatility
1.1×
volume spike